## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Tatsuhiko Kodama et al. Art Unit : 1653

Title : ANTIBODIES THAT INHIBIT TRANSPORT ACTIVITY OF PEPTIDE

TRANSPORTERS

## MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. A copy of the listed U.S. patent can be provided upon request. A translation of reference AC is not included, since it is a member of the patent family of reference AD. Reference AB is the same as reference AD, so it is not separately provided. Also enclosed is a copy of a Supplementary European Search Report received for a counterpart application.

This statement is being filed before the receipt of a first Office Action on the merits.

Please apply any charges or credits to Deposit Account No. 06-1050.

Janis K. Fraser, Ph.D., J.B.

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110 Telephone: (617) 542-5070 Facsimile: (617) 542-8906

21406469.doc

No

Sec AD

See AD

			SHEET I OI I	
Substitute Form PTO-1449 (Modified)			Application No. 10/550,987	
		Applicant Tatsuhiko Kodama et al.		
		Filing Date May 25, 2006	Group Art Unit 1653	

U.S. Patent Documents							
Examiner Initial	Desig.	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,500,346	3/19/1996	Bright et al.			

Australia

Foreign Patent Documents or Published Foreign Patent Applications Country or Patent Office Examiner Desig. Document Publication Translation Initial ID Number Date Class Subclass Yes 06/19/1997

> 09/27/1999 Korea

AB AU 9676557

AC

next communication to applicant.

KR 1999-0071666

	AD	WO 97/19919	06/05/1997	WIPO	English abstract
	Other D	ocuments (inc	lude Author	Title, Date, a	and Place of Publication)
Examiner Initial	Desig. ID	Document			
	AE	Basu et al., "Screening of Anti-PepT1 Antibodies Using Indirect ELISA," Pharmaceutical Research, 13(9 Suppl.):S-37, Abstract No. APQ 1137 (1996)			
	AF	Houdebine, "Tran	sgenic animal bio	reactors," Transge	mic Res., 9:305-320 (2000)
	AG	Kolb et al., "Insert recombination," G			ein locus by Cre-mediated site specific
	AH	Lariviere et al., "T Pharmacol. Exp. 1			gesia: Mutation or Background Genotype?" J.

AG	Kolb et al., "Insertion of a foreign gene into the β-casein locus by Cre-mediated site specific recombination," Gene, 227:21-31 (1999)
AH	Lariviere et al., "Transgenic Studies of Pain and Analgesia: Mutation or Background Genotype?" J. Pharmacol. Exp. Ther., 297:467-473 (2001)
AI	Leiter, "Mice with targeted gene disruptions or gene insertions for diabetes research: problems, pitfalls, and potential solutions," Diabetologia, 45:296-308 (2002)
AJ	Mancini et al., "Induction of Anti-Hepatitis B Surface Antigen (HBsAg) Antibodies in HBsAg Producing Transgenic Mice: A Possible Way of Circumventing 'Nonresponse' to HBsAg," J. Med. Finol., 39:67-74 (1993)
AK	Murray, "Genetic Modification of Animals in the Next Century," Theriogenology, 51:149-159 (1999)
AL	Sigmund, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," Arterioscler. Thromb. Vasc. Biol., 20:1425-1429 (2000)
AM	Tsuchiya, "Therapeutic Antibody," Presentation, Chugai Pharmaceutical Co., Ltd., 21 pages (January 21, 2003)

Examiner Signature Date Considered EXAMINER. Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with